Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia1
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
It has been proposed that remnants of chylomicrons and very-low-density lipoproteins (VLDL) are atherogenic. We have used an immunochemical method to isolate remnant-like particles (RLP) and measured them in terms of their cholesterol and triglycerides (TG). RLP consist of apoB-48-containing triglyceride-rich lipoproteins and remnant-like VLDL containing apoB-100. The study aim was to look for information from postprandial RLP data that could not be known from other markers of triglyceride-rich lipoproteins and fasting TG and RLP data alone. A total of 41 subjects were studied. Eight subjects had hypertriglyceridemia (HTG) and low high-density lipoprotein (HDL), 14 had combined hyperlipidemia (CH), 5 had the apo E2/2 genotype receiving gemfibrozil, 10 were normolipidemic (NL) controls, and 4 had hypercholesterolemia. As a whole group, there was correlation among 1) fasting TG, RLP cholesterol (RLP-C), and RLP-TG but not VLDL apo B100, VLDL apo B48 and their respective postprandial responses measured as incremental area under the curve (IAUC), 2) fasting TG and postprandial IAUC of RLP-C and RLP-TG, 3) RLP-C IAUC, RLP-TG IAUC, and TG IAUC, retinyl palmitate (RP) IAUC, and VLDL apo B48 IAUC but not VLDL apo B100 IAUC. The HTG/low HDL-C and CH groups had higher IAUC for RLP-C, RLP-TG, TG, and RP than the NL group. Fasting and postprandial RLP were triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group. The HTG/low HDL-C and CH groups had a delay in their RLP-C but not RLP-TG peaks suggesting a delay in hepatic clearance of RLP and/or a protracted period of lipolysis and/or processing of RLP. The fasting and postprandial RLP-C/RLP-TG and RLP-C/TG ratios were elevated in the apo E2/2 group in spite of gemfibrozil therapy. The increment in postprandial RLP was, however, not exaggerated. Our data indicate that 1) postprandial RLP lipemia is enhanced in HTG subjects when compared with NL subjects, 2) postprandial RLP lipemia is proportional to fasting RLP and TG levels and mirrors, to a large extent, increases in postprandial TG, RP, and VLDL apo B48 but not VLDL apo B100, 3) there are compositional differences in fasting and postprandial RLP in the three forms of HTG studied, RLP being triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group, and cholesterol-enriched in the apo E2/2 group, and 4) apo E2/2 subjects had high fasting and postprandial RLP-C concentrations in spite of being on treatment with gemfibrozil and having normal fasting and postprandial TG concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patsch, J. R., Karlin, J. B., Scott, L. W., Smith, L. C., & Gotto, A. M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1449 · Cited by 386 · cited 1×
“The amount and origin of remnants in fasting and postprandial states have also been examined by measurement of plasma TG ( 4 ), chylomicron labeling with retinyl palmitate (5, 6), and quantitation of apoprotein (apo) B-48 and apo B-100 in remnant-containing ultracentrifugal lipoprotein fractions (7‐9).”
MethodFamilial apolipoprotein E deficiency.
Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112704 · Cited by 313
Weintraub, M. S., Eisenberg, S., & Breslow, J. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112926 · Cited by 261
Cohn, J. S., Johnson, E. J., Millar, J. S., Cohn, S. D., Milne, R. W., Marcel, Y. L., Russell, R. M., & Schaefer, E. J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35345-1 · Cited by 248
Cohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156
Karpe, F., Bell, M., Björkegren, J., & Hamsten, A. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.2.199 · Cited by 143
Marcoux, C., Tremblay, M., Nakajima, K., Davignon, J., & Cohn, J. S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32142-8 · Cited by 61
Self-citationMarcoux, C., Hopkins, P. N., Wang, T., Leary, E. T., Nakajima, K., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33455-6 · Cited by 43
Self-citation
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
D. Kolovou, G., P. Mikhailidis, D., Kovar, J., Lairon, D., G. Nordestgaard, B., Chye Ooi, T., Perez-Martinez, P., Bilianou, H., Anagnostopoulou, K., & Panotopoulos, G. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111795495549 · Cited by 306
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B., & Rademaker, A. W. (2007) · Diabetes Care · doi:10.2337/dc07-0015 · Cited by 117
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6666-1 · Cited by 36
“In patients with mixed hyperlipidemia (characterized by elevated triglyceride and cholesterol levels), increased serum concentrations of remnant-like particles derived from either chylomicrons or very low– density lipoprotein (VLDL) are observed [14].”
BackgroundPostprandial lipaemia and vascular disease
Kolovou, G., & Ooi, T. C. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606971 · Cited by 32
Self-citation
Metadata
- Authors
- Ooi, T. C., Cousins, M., Ooi, D. S., Steiner, G., Uffelman, K. D., Nakajima, K., & Simo, I. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-07
- Volume
- 86
- Issue
- 7
- Pages
- 3134-3142
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2046241874
- Cited by
- 55
- References
- 8
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.